NASDAQ:ACLX Arcellx Q2 2024 Earnings Report ProfileEarnings HistoryForecast Arcellx EPS ResultsActual EPS-$0.51Consensus EPS -$0.52Beat/MissBeat by +$0.01One Year Ago EPSN/AArcellx Revenue ResultsActual Revenue$27.38 millionExpected Revenue$22.04 millionBeat/MissBeat by +$5.34 millionYoY Revenue Growth+91.50%Arcellx Announcement DetailsQuarterQ2 2024Date8/8/2024TimeAfter Market ClosesConference Call DateFriday, August 9, 2024Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arcellx Earnings HeadlinesGilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celApril 28, 2026 | businesswire.comGilead extends Arcellx tender offer againApril 17, 2026 | seekingalpha.comHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall of Fame Trader Jon Najarian now says EVERYONE is missing an even bigger story about the SpaceX IPO… That it's just the start of an Elon Musk $44 trillion "Superconvergence…" An event that could kick off as soon as June 12th. | Banyan Hill Publishing (Ad)Truist Financial Keeps Their Hold Rating on Arcellx Inc (ACLX)April 10, 2026 | theglobeandmail.comAssessing Arcellx (ACLX) Valuation After Strong Multi‑Year Share Price GainsApril 8, 2026 | finance.yahoo.comAssessing Arcellx (ACLX) Valuation After Strong Multi Period Share Price MomentumMarch 25, 2026 | finance.yahoo.comSee More Arcellx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcellx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcellx and other key companies, straight to your email. Email Address About ArcellxArcellx (NASDAQ:ACLX) (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers. The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development. Arcellx is advancing lead clinical candidates for relapsed or refractory blood cancers, while exploring applications in solid tumors and autoimmune indications. Manufacturing operations are conducted at the company’s proprietary facility in Malvern, Pennsylvania, with additional process development and scale-up capabilities in the greater Philadelphia region. Founded in 2018, Arcellx has established collaborations with academic centers and contract research organizations across North America and Europe to support its clinical trial activities. The company is led by an experienced management team with deep expertise in cell therapy research, clinical development and biomanufacturing. Arcellx’s leadership is committed to translating its engineered cell technology into novel treatments that can overcome the limitations of current approaches and address significant unmet medical needs.View Arcellx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Abercrombie Rallies as Strong Q1 Earnings Extend Winning StreakZscaler Stock Drops 30%: Why the Dip Is a Buy OpportunityRecord Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy?Micron’s $1 Trillion Memory Melt-UpKeysight: The AI and Defense Stock Seeing Big Price Target BoostsAutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Upcoming Earnings Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026)Dell Technologies (5/28/2026)Royal Bank Of Canada (5/28/2026)Toronto Dominion Bank (5/28/2026)Hewlett Packard Enterprise (6/1/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
